Triphendiol clinical trial application filed

An application for a clinical trial has been filed for Triphendiol, which has orphan drug status, to be used as a chemosensitizing agent with gemcitabine.

There is a lot to be hopeful for here, some of the highlights:

-looks like the trial would be open to patients with unresectable, locally advanced or metastatic pancreatic and bile duct cancers (many trials exclude those with metastases)

-orally delivered

-exhibits high selectivity, little effect on non-tumor cells and no observable toxicity in animals at therapeutically effective doses

-in human studies conducted in Australia, no adverse events or side effects have been reported

Read the full press release here:

http://www.novogen.com/news/news0501.cfm?mainsection=05&subsection=01&newsid=309

Librarian Patty